EVQ 222
Alternative Names: EVQ-222; EVQ-222-COV; EVQ-222-VIALatest Information Update: 30 Jun 2023
At a glance
- Originator EVOQ Bio
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research COVID 2019 infections; Influenza A virus infections
Most Recent Events
- 06 Jun 2023 EVQ 222 is available for licensing as of 06 Jun 2023. https://evoqbio.com/pipeline/
- 02 Jun 2023 Early research in COVID-2019 infections in USA (unspecified route), prior to June 2023 (EVOQ Bio pipeline, June 2023)
- 02 Jun 2023 Early research in Influenza A virus infections in USA (unspecified route) prior to June 2023 (EVOQ Bio pipeline, June 2023)